The announcement time of this financial report is: 2023-10-20 16:03:14

Guangji Pharmaceutical Co., Ltd. (stock code: 000952) is a pharmaceutical manufacturing enterprise mainly engaged in the research, development, production and sales of vitamin B2, B6 raw materials and pharmaceutical preparation products. The company has established a research and development center with raw materials and preparations as the core and a number of supporting subsidiaries, and has developed into a modern pharmaceutical enterprise integrating R & D, production and sales.

According to the summary of Guangji Pharmaceutical's financial report for the third quarter of 2023, the net asset at the end of this report was 1.483 billion yuan, down slightly from 1.492 billion yuan at the end of the previous year. This may be related to the company's operating activities during the reporting period, and further analysis of the company's specific operating conditions is needed to determine the reasons for the slight decline in net assets.

At the same time, the asset-liability ratio was 53.33% at the end of the reporting period, up from 39.58% at the end of the previous year. This indicates that the debt scale of the company is expanding, which may be due to the increase of debt due to the expansion of production and operation scale or investment activities.

In terms of profitability, Guangji Pharmaceutical's gross profit margin was 28.83% in the third quarter of 2023, down from 34.7% in the same period last year. This may be related to a decrease in sales revenue or an increase in costs. At the same time, the net profit in the reporting period was-718 million yuan, compared with 183 million yuan in the same period last year, the company's profit situation has changed greatly, from profit to loss. This may be due to a decrease in the company's operating income or an increase in costs and expenses.

To sum up, Guangji Pharmaceutical has experienced some adverse changes in its financial position in the third quarter of 2023. The slight decline in net assets and the increase in asset-liability ratio indicate that the financial risk of the company has increased, which needs to attract the attention of investors. At the same time, the change of net profit from profit to loss also shows the decline of the company's profitability.

In view of the above situation, Guangji Pharmaceutical Company needs to further analyze its specific operation situation and find out the reasons for the slight decline in net assets and the negative net profit. Possible reasons include reduced sales revenue, increased costs, and so on. Companies can improve profitability by optimizing product structure, increasing sales and controlling costs. In addition, the company should also strengthen fund management and reasonably plan investment activities in order to reduce asset-liability ratio and control financial risks.

Although Guangji Pharmaceutical is facing some challenges in the third quarter of 2023, as a pharmaceutical manufacturing enterprise mainly engaged in the research, development, production and sales of vitamin B2 and B6 raw material products and pharmaceutical preparation products, the company still has certain market competitiveness and development potential. Investors should pay close attention to the business dynamics and financial performance of the company in order to make wise investment decisions.

This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.